Long term outcomes of participants in the PARAMEDIC2 randomised trial of adrenaline in out-of-hospital cardiac arrest

Research output: Contribution to journalArticlepeer-review

Standard

Long term outcomes of participants in the PARAMEDIC2 randomised trial of adrenaline in out-of-hospital cardiac arrest. / Haywood, Kirstie L; Ji, Chen; Quinn, Tom; Nolan, Jerry P; Deakin, Charles D; Scomparin, Charlotte; Lall, Ranjit; Gates, Simon; Long, John; Regan, Scott; Fothergill, Rachael T; Pocock, Helen; Rees, Nigel; O'Shea, Lyndsey; Perkins, Gavin D.

In: Resuscitation, Vol. 160, 03.2021, p. 84-93.

Research output: Contribution to journalArticlepeer-review

Harvard

Haywood, KL, Ji, C, Quinn, T, Nolan, JP, Deakin, CD, Scomparin, C, Lall, R, Gates, S, Long, J, Regan, S, Fothergill, RT, Pocock, H, Rees, N, O'Shea, L & Perkins, GD 2021, 'Long term outcomes of participants in the PARAMEDIC2 randomised trial of adrenaline in out-of-hospital cardiac arrest', Resuscitation, vol. 160, pp. 84-93. https://doi.org/10.1016/j.resuscitation.2021.01.019

APA

Haywood, K. L., Ji, C., Quinn, T., Nolan, J. P., Deakin, C. D., Scomparin, C., Lall, R., Gates, S., Long, J., Regan, S., Fothergill, R. T., Pocock, H., Rees, N., O'Shea, L., & Perkins, G. D. (2021). Long term outcomes of participants in the PARAMEDIC2 randomised trial of adrenaline in out-of-hospital cardiac arrest. Resuscitation, 160, 84-93. https://doi.org/10.1016/j.resuscitation.2021.01.019

Vancouver

Author

Haywood, Kirstie L ; Ji, Chen ; Quinn, Tom ; Nolan, Jerry P ; Deakin, Charles D ; Scomparin, Charlotte ; Lall, Ranjit ; Gates, Simon ; Long, John ; Regan, Scott ; Fothergill, Rachael T ; Pocock, Helen ; Rees, Nigel ; O'Shea, Lyndsey ; Perkins, Gavin D. / Long term outcomes of participants in the PARAMEDIC2 randomised trial of adrenaline in out-of-hospital cardiac arrest. In: Resuscitation. 2021 ; Vol. 160. pp. 84-93.

Bibtex

@article{37e160623b7d4baca235420e9eab090f,
title = "Long term outcomes of participants in the PARAMEDIC2 randomised trial of adrenaline in out-of-hospital cardiac arrest",
abstract = "AIMS: We recently reported early outcomes in patients enrolled in a randomised trial of adrenaline in out-of-hospital cardiac arrest: the PARAMEDIC2 (Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration in Cardiac Arrest) trial. The purpose of the present paper is to report long-term survival, quality of life, functional and cognitive outcomes at 3, 6 and 12-months.METHODS: PARAMEDIC2 was a pragmatic, individually randomised, double blind, controlled trial with an economic evaluation. Patients were randomised to either adrenaline or placebo. This paper reports results on the modified Rankin Scale scores at 6-months, survival at 6 and 12-months, as well as other cognitive, functional and quality of life outcomes collected at 3 and 6 months (Two Simple Questions, the Mini Mental State Examination, the Informant Questionnaire on Cognitive Decline Evaluation for Cardiac Arrest, Hospital Anxiety and Depression Scale, the Post Traumatic Stress Disorder Checklist - Civilian Version, Short-Form 12-item Health Survey and the EuroQoL EQ-5D-5L).RESULTS: 8,014 patients were randomised with confirmed trial drug administration. At 6-months, 78 (2.0%) of the patients in the adrenaline group and 58 (1.5%) of patients in the placebo group had a favourable neurological outcome (adjusted odds ratio 1.35 [95% confidence interval: 0.93, 1.97]). 117 (2.9%) patients were alive at 6-months in the adrenaline group compared with 86 (2.2%) in the placebo group (1.43 [1.05, 1.96], reducing to 107 (2.7%) and 80 (2.0%) respectively at 12-months (1.38 [1.00, 1.92]). Measures of 3 and 6-month cognitive, functional and quality of life outcomes were reduced, but there was no strong evidence of differences between groups.CONCLUSION: Adrenaline improved survival through to 12-months follow-up. The study did not find evidence of improvements in favourable neurological outcomes. (ISCRTN 73485024).",
keywords = "Adrenaline, Cardiac arrest, Cognitive, Drugs, Functional, Health related quality of life, Long term",
author = "Haywood, {Kirstie L} and Chen Ji and Tom Quinn and Nolan, {Jerry P} and Deakin, {Charles D} and Charlotte Scomparin and Ranjit Lall and Simon Gates and John Long and Scott Regan and Fothergill, {Rachael T} and Helen Pocock and Nigel Rees and Lyndsey O'Shea and Perkins, {Gavin D}",
note = "Funding Information: Dr. Quinn reports grants from National Institute for Health Research, during the conduct of the study; grants from British Heart Foundation, grants from the Gas Safety Trust, outside the submitted work. The trial was funded by the NIHR Health Technology Assessment Programme , grant number 12/127/126 and supported by NIHR Applied Research Collaboration West Midlands and Health and Care Research Wales. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Dr. Perkins reports grants from National Institute for Health Research, during the conduct of the study; grants from British Heart Foundation, grants from Resuscitation Council UK, non-financial support from European Resuscitation Council, non-financial support from International Liaison Committee on Resuscitation, outside the submitted work. Publisher Copyright: {\textcopyright} 2021 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = mar,
doi = "10.1016/j.resuscitation.2021.01.019",
language = "English",
volume = "160",
pages = "84--93",
journal = "Resuscitation",
issn = "0300-9572",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Long term outcomes of participants in the PARAMEDIC2 randomised trial of adrenaline in out-of-hospital cardiac arrest

AU - Haywood, Kirstie L

AU - Ji, Chen

AU - Quinn, Tom

AU - Nolan, Jerry P

AU - Deakin, Charles D

AU - Scomparin, Charlotte

AU - Lall, Ranjit

AU - Gates, Simon

AU - Long, John

AU - Regan, Scott

AU - Fothergill, Rachael T

AU - Pocock, Helen

AU - Rees, Nigel

AU - O'Shea, Lyndsey

AU - Perkins, Gavin D

N1 - Funding Information: Dr. Quinn reports grants from National Institute for Health Research, during the conduct of the study; grants from British Heart Foundation, grants from the Gas Safety Trust, outside the submitted work. The trial was funded by the NIHR Health Technology Assessment Programme , grant number 12/127/126 and supported by NIHR Applied Research Collaboration West Midlands and Health and Care Research Wales. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Dr. Perkins reports grants from National Institute for Health Research, during the conduct of the study; grants from British Heart Foundation, grants from Resuscitation Council UK, non-financial support from European Resuscitation Council, non-financial support from International Liaison Committee on Resuscitation, outside the submitted work. Publisher Copyright: © 2021 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/3

Y1 - 2021/3

N2 - AIMS: We recently reported early outcomes in patients enrolled in a randomised trial of adrenaline in out-of-hospital cardiac arrest: the PARAMEDIC2 (Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration in Cardiac Arrest) trial. The purpose of the present paper is to report long-term survival, quality of life, functional and cognitive outcomes at 3, 6 and 12-months.METHODS: PARAMEDIC2 was a pragmatic, individually randomised, double blind, controlled trial with an economic evaluation. Patients were randomised to either adrenaline or placebo. This paper reports results on the modified Rankin Scale scores at 6-months, survival at 6 and 12-months, as well as other cognitive, functional and quality of life outcomes collected at 3 and 6 months (Two Simple Questions, the Mini Mental State Examination, the Informant Questionnaire on Cognitive Decline Evaluation for Cardiac Arrest, Hospital Anxiety and Depression Scale, the Post Traumatic Stress Disorder Checklist - Civilian Version, Short-Form 12-item Health Survey and the EuroQoL EQ-5D-5L).RESULTS: 8,014 patients were randomised with confirmed trial drug administration. At 6-months, 78 (2.0%) of the patients in the adrenaline group and 58 (1.5%) of patients in the placebo group had a favourable neurological outcome (adjusted odds ratio 1.35 [95% confidence interval: 0.93, 1.97]). 117 (2.9%) patients were alive at 6-months in the adrenaline group compared with 86 (2.2%) in the placebo group (1.43 [1.05, 1.96], reducing to 107 (2.7%) and 80 (2.0%) respectively at 12-months (1.38 [1.00, 1.92]). Measures of 3 and 6-month cognitive, functional and quality of life outcomes were reduced, but there was no strong evidence of differences between groups.CONCLUSION: Adrenaline improved survival through to 12-months follow-up. The study did not find evidence of improvements in favourable neurological outcomes. (ISCRTN 73485024).

AB - AIMS: We recently reported early outcomes in patients enrolled in a randomised trial of adrenaline in out-of-hospital cardiac arrest: the PARAMEDIC2 (Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration in Cardiac Arrest) trial. The purpose of the present paper is to report long-term survival, quality of life, functional and cognitive outcomes at 3, 6 and 12-months.METHODS: PARAMEDIC2 was a pragmatic, individually randomised, double blind, controlled trial with an economic evaluation. Patients were randomised to either adrenaline or placebo. This paper reports results on the modified Rankin Scale scores at 6-months, survival at 6 and 12-months, as well as other cognitive, functional and quality of life outcomes collected at 3 and 6 months (Two Simple Questions, the Mini Mental State Examination, the Informant Questionnaire on Cognitive Decline Evaluation for Cardiac Arrest, Hospital Anxiety and Depression Scale, the Post Traumatic Stress Disorder Checklist - Civilian Version, Short-Form 12-item Health Survey and the EuroQoL EQ-5D-5L).RESULTS: 8,014 patients were randomised with confirmed trial drug administration. At 6-months, 78 (2.0%) of the patients in the adrenaline group and 58 (1.5%) of patients in the placebo group had a favourable neurological outcome (adjusted odds ratio 1.35 [95% confidence interval: 0.93, 1.97]). 117 (2.9%) patients were alive at 6-months in the adrenaline group compared with 86 (2.2%) in the placebo group (1.43 [1.05, 1.96], reducing to 107 (2.7%) and 80 (2.0%) respectively at 12-months (1.38 [1.00, 1.92]). Measures of 3 and 6-month cognitive, functional and quality of life outcomes were reduced, but there was no strong evidence of differences between groups.CONCLUSION: Adrenaline improved survival through to 12-months follow-up. The study did not find evidence of improvements in favourable neurological outcomes. (ISCRTN 73485024).

KW - Adrenaline

KW - Cardiac arrest

KW - Cognitive

KW - Drugs

KW - Functional

KW - Health related quality of life

KW - Long term

UR - http://www.scopus.com/inward/record.url?scp=85100424089&partnerID=8YFLogxK

U2 - 10.1016/j.resuscitation.2021.01.019

DO - 10.1016/j.resuscitation.2021.01.019

M3 - Article

C2 - 33524488

VL - 160

SP - 84

EP - 93

JO - Resuscitation

JF - Resuscitation

SN - 0300-9572

ER -